1.Chang M-H, You S-L, Chen C-J, Liu C-J, Lai M-W, Wu T-C, et al. Long- term effects of hepatitis B
immunization of infants in preventing liver cancer. Gastroenterology 2016:21–26.

2. Catharina J Alberts, Gary M Clifford, Damien Georges, Francesco Negro, Olufunmilayo A Lesi, Yvan J-F Hutin,
 Catherine de Martel. Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with
Cirrhosis at country, region,and global levels: a systematic review. Lancet Gastroenterol Hepatol 2022; 7: 724–35. 

3. Christoph Roderburg Frank Tacke Christian Trautwein.Antiviral Therapy in Patients with Viral Hepatitis and
Hepatocellular Carcinoma: Indications and Prognosis. Visc Med 2016;32:121–126 

2.    European Association for the Study of the Liver. EASL Recommenda- tions on Treatment of Hepatitis C 2018. J Hepatol 2018. https://doi.org/10.1016/j.jhep.2018.03.026.  

3.    Papatheodoridis GV, Idilman R, Dalekos GN, Buti M, Chi H, van Boemmel F, et al. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatology 2017;66:1444–1453.   

4.    Su T-H, Hu T-H, Chen C-Y, Huang Y-H, Chuang W-L, Lin C-C, et al. Four- year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver Int 2016;36:1755– 1764.    

5.    van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour J-F, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584.  

6.    . Inoue M, Yoshimi I, Sobue T, Tsugane S. Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: a prospective study in Japan. J Natl Cancer Inst 2005;97:293–300.  

7.    Setiawan VW, Wilkens LR, Lu SC, Hernandez BY, Le Marchand L, Henderson BE. Association of coffee intake with reduced incidence of liver cancer and death from chronic liver disease in the US multiethnic cohort. Gastroenterology 2015;148:118–25; quiz e15.  

8.    Zhang B.H., Yang B.H., Tang Z.Y. (2004) Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 130: 417– 422.  

9.    Amit G. Singal, Emily Zhang, Manasa Narasimman, Nicole E. Rich, Akbar K. Waljee, Yujin Hoshida, Ju Dong Yang, Maria Reig, Giuseppe Cabibbo, Pierre Nahon, Neehar D  Parikh, Jorge A Marrero, HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A metaanalysis,Journal of Hepatology,Volume 77,Issue1,Julyl  2022,Pages 128-139.  

10.  Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48(2):335–52.

11.  Nicole J. Kim,1 Philip Vutien, Erin Cleveland,1 Anne Cravero, and George N. Ioannou1. Fibrosis Stage-specific Incidence of Hepatocellular Cancer After Hepatitis C Cure With Direct-acting Antivirals: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology 2023;21:1723–1738.

12.  Ioannou GN, Green P, Kerr KF, Berry K. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD- related cirrhosis for risk stratification. J Hepatol 2019;71:523- 533.

15.Singal AG, Ghaziani T, Zhou K, Grinspan L, Benhammou J, Moon A, et al. Recall patterns and risk of primary     liver cancer for sub-centimeter ultrasound liverobservations: A multicenter study. Hepatology Communications.
2023;7(3):e0073.

16. Roberts LR, Sirlin CB, Zaiem F, Almasri J, Prokop LJ, Heimbach JK, et al. Imaging for the diagnosis of       hepatocellular carcinoma: A systematic review and metaanalysis. Hepatol- ogy. 2018;67:401–21.

17. Dong Hyun Sinn, Gyu-Seong Choi, Hee Chul ParkID, Jong Man Kim, Honsoul Kim,Kyoung et al.Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients.January 2019.PLoS ONE14(1):e0210730.

18.Hanna RF, Miloushev VZ, Tang A, Finklestone LA, Brejt SZ, Sandhu RS, et al. Comparative 13-year meta-       analysis of the sensitivity and positive predictive value of ultrasound, CT, and MRI for detecting hepatocellular      carcinoma. Abdom Radiol (NY). 2016;41:71–90.

19.Lee YJ, Lee JM, Lee JS, et al. Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis. Radiology. 2015;275:97e109.

20. Luca Di Tommaso, Marco Spadaccini, Matteo Donadon, Nicola Personeni, Abubaker Elamin, Alessio Aghemo,Ana Lleo. Role of liver biopsy in hepatocellular carcinoma. World J Gastroenterol 2019 October 28; 25(40): 6041-6052.

21.Forner A, Vilana R, Ayuso C, Bianchi L, Solé M, Ayuso JR, et al. Diagnosis of hepatic nodules 20 mm or  smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma.Hepatology 2008;47:97–104.

22.Cabibbo G, Enea M, Attanasio M, Bruix J, Craxi A, Camma C. A meta- analysis of survival rates of   patients in randomized clinical trials of hepatocellular carcinoma. Hepatology 2010;51:1274–1283. 

23. Lei Chang, Yitao Wang, Jibo Zhang and Tao Guo1. The best strategy for HCC patients at each BCLC stage: a network meta-analysis of observational studies. Oncotarget, 2017, Vol. 8, (No. 12), pp: 20418-20427.

24.Marrero JA, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL, et al. Prognosis of hepatocellular       carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005;41:707–716.

25.Miller G, Schwartz LH, D'Angelica M. The use of imaging in the diagnosis and staging of hepatobiliary       malignancies. Surg Oncol Clin N Am 2007;16:343-368. Available http://www.ncbi.nlm.nih.gov/pubmed/17560517.

26.Cabibo G,Attanasio M,BruixJ,Craxi A,Camma C. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology (Baltimore, Md.), 01 Apr 2010, 51(4):1274-1283

27.Cooper GS, Bellamy P, Dawson NV, et al. A prognostic model for patients with end-stage liver disease. Gastroenterology        1997;113:12781288. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9322523.

28.Jie Chen, Yujen Tseng, Tiancheng Luo, Na Li, Lili Ma, Shiyao Chenille . Prophylactic Endoscopic Therapy for Variceal Bleeding in Patients with Hepatocellular Carcinoma. J Cancer 2019; 10(14):3087-3093. doi:10.7150/jca.30434

29. Sun DW, An L, Wei F, et al. Prognostic significance of parameters from pretreatment (18)F-FDG PET in hepatocellular carcinoma: a meta-analysis. Abdom Radiol (NY) 2016;41:33-41

30. Byungje Bae, Keera Kang, Sung Kyu Song, Chul-Woon Chung, Yongkeun Park. Is partial hepatectomy a curable treatment option for hepatocellular carcinoma accompanied by cirrhosis? A meta-analysis and cure model analysis. Ann Hepatobiliary Pancreat Surg 2022;26:4757.

31.Senbel A, Elmahdy Y, Roshdy S, et al. Role of Hepatic Resection for HCC in the era of Transplantation; an Experience of Two Tertiary Egyptian Centers. Indian J Surg Oncol. 2017;8(4):514–518.
 doi:10.1007/s131930170679-5.  

32.Yu Huang, Wenhao Ge, Yang Kong, Yuan Ding, et al. Preoperative Portal Vein Embolization for Liver Resection: An updated meta-analysis. Journal of Cancer 2021, Vol. 12(6): 1770-1778.

 33.OPTN/UNOS policy notice modification to hepatocellular carcinoma (HCC) extension criteria. Available at: https://optn.transplant.hrsa.gov/media/2411/modification-to-hcc-autoapproval-criteria_policy-notice. 

34.Antonio Facciorusso  , Mohamed A. Abd El Aziz  , Nicola Tartaglia  , Daryl Ramai , et al. Microwave Ablation Versus Radiofrequency Ablation for Treatment of Hepatocellular Carcinoma:
A Meta-Analysis of Randomized Controlled Trials. Cancers 2020, 12, 3796.

 35. Francesco Izzo, VincenzaI Granta, Roberta Grassi,Roberta Fusco, et al. Radiofrequency Ablation
 And Microwave Ablation in Liver Tumors: An Update. The Oncologist 2019;24:e990–. e1005.

36. Yun Ku Cho, Jae Kyun Kim, Mi Young Kim, Hyunchul Rhim, et al.Systematic Review of Randomized
Trials for Hepatocellular Carcinoma Treated with Percutaneous Ablation Therapies. Hepatology.
 2009;49(2):453–9.

37. Swierz MJ, Storman D, Riemsma RP, Wolff R, et al. Percutaneous ethanol injection for liver
metastases(Systematic Review). Cochrane Database of Systematic Reviews 2020, Issue 2. Art. No.:   CD008717.

38. Yanyan Long, Yan Liang, Shujie Li1, Jing Guo1, et.al. Therapeutic outcome and related predictors of
Stereotactic  body radiotherapy for small liver-confined HCC: a systematic review and meta-analysis of
observational studies. Radiat Oncol (2021) 16:68 https://doi.org/10.1186/s13014-021-01761-1    

39. Yi Yang, Zhuo-Min Lv, Min Yan, Hong-Xin Zhang,et al. Transarterial chemoembolization combined
 With radiofrequency ablation in the treatment of hepatocellular carcinoma. April 2019.Hepatoma Rsearch 5.

40. Chao Yin, Samantha Armstrong, Richard Shin, Xue Geng, et al. Bridging and downstaging with TACE
in early and intermediate stage hepatocellular carcinoma: Predictors of receiving a liver transplant. Ann
Gastroenterol Surg.2023;7:295–305. 

41.Llovet J,Josep M. Systematic review of randomized trials for unresectable hepatocellular carcinoma:
chemoembolization improves survival. Hepatology. 2003;37(2):429–442. doi:10.1053/jhep.2003.50047.

42. Lencioni, Riccardo^*; de Baere, Thierry; Soulen, et al. Lipiodol transarterial chemoembolization for
Hepatocellular carcinoma: A systematic review of efficacy and safety data. Hepatology 64(1):p 106-
116,7/2016-116,7/2016.    July 2016.

43.Terzi E,Golfiieri R,Piscaglia F,Giampalma E.Response rate and clinical outcome of HCC after first and repeated
TAC performed “on demand”. Journal of hepatology.Volume 57,Issue6,P1258-1267,12/2012.